PacBio’s earnings surpassed the Zacks Consensus ... Joining the 10X Genomics Compatible Partner program integrates Onso into single-cell and spatial biology workflows, addressing growing market ...

PacBio’s earnings surpassed the Zacks Consensus ... Continued strong prospects in the Revio and Onso systems, with customers placing orders for these, looked promising for the stock.

https://www.tipranks.com/news/the-fly/veeva-price-target-raised-to-245-from-240-at-scotiabank Canaccord reiterates a Buy rating on PacBio (PACB) with a $3 price ...

University of Washington & UDN Research: Demonstrated PacBio’s ability to simultaneously analyze the genome, methylome, epigenome, and transcriptome, providing novel insights into a rare and ...

Genomics company Pacific Biosciences of California (NASDAQ:PACB) missed Wall Street’s revenue expectations in Q4 CY2024, with sales falling 32.8% year on year to $39.22 million. Its non-GAAP ...

20:11 EST Cathie Wood’s ARK Investment bought 344K shares of PacBio (PACB) today Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and ...

MENLO PARK, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation ...

MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be ...

MENLO PARK, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee ...